U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C29H31N7O.CH4O3S
Molecular Weight 589.7106
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IMATINIB MESYLATE

SMILES

Cc1ccc(cc1Nc2nccc(-c3cccnc3)n2)NC(=O)c4ccc(cc4)CN5CCN(C)CC5.CS(=O)(=O)O

InChI

InChIKey=YLMAHDNUQAMNNX-UHFFFAOYSA-N
InChI=1S/C29H31N7O.CH4O3S/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36;1-5(2,3)4/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34);1H3,(H,2,3,4)

HIDE SMILES / InChI

Molecular Formula CH4O3S
Molecular Weight 96.1068
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C29H31N7O
Molecular Weight 493.6038
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/2009892

Imatinib (GLEEVEC®) is a tyrosine kinase inhibitor and antineoplastic agent that inhibits the BCR-ABL tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in chronic myeloid leukaemia (CML). It inhibits proliferation and induces apoptosis in BCR-ABL positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive CML. Imatinib (GLEEVEC®) inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. It is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGF- and SCF-mediated cellular events. In vitro, imatinib (GLEEVEC®) inhibits proliferation and induces apoptosis in gastrointestinal stromal tumor (GIST) cells, which express an activating c-kit mutation.

CNS Activity

Curator's Comment:: Imatinib poorly penetrates the blood-brain barrier and has limited activity against CNS leukaemia.

Originator

Curator's Comment:: # Ciba-Geigy Ltd. (now Novartis)

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
GLEEVEC

Approved Use

Gleevec is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (1.1) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy (1.2) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) (1.3) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy (1.4) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements (1.5) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown (1.6) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown (1.7) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP) (1.8) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST) (1.9) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST (1.10) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase. 1.2 Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) After Interferon-alpha (IFN) Therapy Patients with Philadelphia chromosome positive chronic myeloid leukemia in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. 1.3 Adult patients with Ph+ Acute Lymphoblastic Leukemia (ALL) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia. 1.4 Pediatric patients with Ph+ Acute Lymphoblastic Leukemia (ALL) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. 1.5 Myelodysplastic/Myeloproliferative Diseases (MDS/MPD) Adult patients with myelodysplastic/myeloproliferative diseases associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. 1.6 Aggressive Systemic Mastocytosis (ASM) Adult patients with aggressive systemic mastocytosis without the D816V c-Kit mutation or with c-Kit mutational status unknown. 1.7 Hypereosinophilic Syndrome (HES) and/or Chronic Eosinophilic Leukemia (CEL) Adult patients with hypereosinophilic syndrome and/or chronic eosinophilic leukemia who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. 1.8 Dermatofibrosarcoma Protuberans (DFSP) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans. 1.9 Kit+ Gastrointestinal Stromal Tumors (GIST) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors. 1.10 Adjuvant Treatment of GIST Adjuvant treatment of adult patients following complete gross resection of Kit (CD117) positive GIST.

Launch Date

9.8945283E11
Primary
GLEEVEC

Approved Use

Gleevec is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (1.1) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy (1.2) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) (1.3) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy (1.4) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements (1.5) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown (1.6) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown (1.7) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP) (1.8) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST) (1.9) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST (1.10) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase. 1.2 Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) After Interferon-alpha (IFN) Therapy Patients with Philadelphia chromosome positive chronic myeloid leukemia in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. 1.3 Adult patients with Ph+ Acute Lymphoblastic Leukemia (ALL) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia. 1.4 Pediatric patients with Ph+ Acute Lymphoblastic Leukemia (ALL) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. 1.5 Myelodysplastic/Myeloproliferative Diseases (MDS/MPD) Adult patients with myelodysplastic/myeloproliferative diseases associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. 1.6 Aggressive Systemic Mastocytosis (ASM) Adult patients with aggressive systemic mastocytosis without the D816V c-Kit mutation or with c-Kit mutational status unknown. 1.7 Hypereosinophilic Syndrome (HES) and/or Chronic Eosinophilic Leukemia (CEL) Adult patients with hypereosinophilic syndrome and/or chronic eosinophilic leukemia who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. 1.8 Dermatofibrosarcoma Protuberans (DFSP) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans. 1.9 Kit+ Gastrointestinal Stromal Tumors (GIST) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors. 1.10 Adjuvant Treatment of GIST Adjuvant treatment of adult patients following complete gross resection of Kit (CD117) positive GIST.

Launch Date

9.8945283E11
Primary
GLEEVEC

Approved Use

Gleevec is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (1.1) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy (1.2) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) (1.3) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy (1.4) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements (1.5) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown (1.6) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown (1.7) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP) (1.8) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST) (1.9) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST (1.10) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase. 1.2 Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) After Interferon-alpha (IFN) Therapy Patients with Philadelphia chromosome positive chronic myeloid leukemia in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. 1.3 Adult patients with Ph+ Acute Lymphoblastic Leukemia (ALL) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia. 1.4 Pediatric patients with Ph+ Acute Lymphoblastic Leukemia (ALL) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. 1.5 Myelodysplastic/Myeloproliferative Diseases (MDS/MPD) Adult patients with myelodysplastic/myeloproliferative diseases associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. 1.6 Aggressive Systemic Mastocytosis (ASM) Adult patients with aggressive systemic mastocytosis without the D816V c-Kit mutation or with c-Kit mutational status unknown. 1.7 Hypereosinophilic Syndrome (HES) and/or Chronic Eosinophilic Leukemia (CEL) Adult patients with hypereosinophilic syndrome and/or chronic eosinophilic leukemia who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. 1.8 Dermatofibrosarcoma Protuberans (DFSP) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans. 1.9 Kit+ Gastrointestinal Stromal Tumors (GIST) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors. 1.10 Adjuvant Treatment of GIST Adjuvant treatment of adult patients following complete gross resection of Kit (CD117) positive GIST.

Launch Date

9.8945283E11
Primary
GLEEVEC

Approved Use

Gleevec is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (1.1) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy (1.2) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) (1.3) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy (1.4) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements (1.5) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown (1.6) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown (1.7) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP) (1.8) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST) (1.9) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST (1.10) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase. 1.2 Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) After Interferon-alpha (IFN) Therapy Patients with Philadelphia chromosome positive chronic myeloid leukemia in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. 1.3 Adult patients with Ph+ Acute Lymphoblastic Leukemia (ALL) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia. 1.4 Pediatric patients with Ph+ Acute Lymphoblastic Leukemia (ALL) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. 1.5 Myelodysplastic/Myeloproliferative Diseases (MDS/MPD) Adult patients with myelodysplastic/myeloproliferative diseases associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. 1.6 Aggressive Systemic Mastocytosis (ASM) Adult patients with aggressive systemic mastocytosis without the D816V c-Kit mutation or with c-Kit mutational status unknown. 1.7 Hypereosinophilic Syndrome (HES) and/or Chronic Eosinophilic Leukemia (CEL) Adult patients with hypereosinophilic syndrome and/or chronic eosinophilic leukemia who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. 1.8 Dermatofibrosarcoma Protuberans (DFSP) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans. 1.9 Kit+ Gastrointestinal Stromal Tumors (GIST) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors. 1.10 Adjuvant Treatment of GIST Adjuvant treatment of adult patients following complete gross resection of Kit (CD117) positive GIST.

Launch Date

9.8945283E11
Primary
GLEEVEC

Approved Use

Gleevec is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (1.1) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy (1.2) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) (1.3) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy (1.4) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements (1.5) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown (1.6) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown (1.7) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP) (1.8) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST) (1.9) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST (1.10) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase. 1.2 Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) After Interferon-alpha (IFN) Therapy Patients with Philadelphia chromosome positive chronic myeloid leukemia in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. 1.3 Adult patients with Ph+ Acute Lymphoblastic Leukemia (ALL) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia. 1.4 Pediatric patients with Ph+ Acute Lymphoblastic Leukemia (ALL) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. 1.5 Myelodysplastic/Myeloproliferative Diseases (MDS/MPD) Adult patients with myelodysplastic/myeloproliferative diseases associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. 1.6 Aggressive Systemic Mastocytosis (ASM) Adult patients with aggressive systemic mastocytosis without the D816V c-Kit mutation or with c-Kit mutational status unknown. 1.7 Hypereosinophilic Syndrome (HES) and/or Chronic Eosinophilic Leukemia (CEL) Adult patients with hypereosinophilic syndrome and/or chronic eosinophilic leukemia who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. 1.8 Dermatofibrosarcoma Protuberans (DFSP) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans. 1.9 Kit+ Gastrointestinal Stromal Tumors (GIST) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors. 1.10 Adjuvant Treatment of GIST Adjuvant treatment of adult patients following complete gross resection of Kit (CD117) positive GIST.

Launch Date

9.8945283E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.74 mg/L
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IMATINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
4478 ng/mL
500 mg 2 times / day steady-state, oral
dose: 500 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
IMATINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1907.5 ng/mL
400 mg 1 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
IMATINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3508.9 ng/mL
600 mg 1 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
IMATINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1907.5 ng/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IMATINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
4.82 μg/mL
600 mg 2 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IMATINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
4.75 μg/mL
500 mg 2 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IMATINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.71 μg/mL
600 mg 2 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CGP-74588 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1.18 μg/mL
500 mg 2 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CGP-74588 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
19.9 mg × h/L
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IMATINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
174.1 ng × h/mL
500 mg 2 times / day steady-state, oral
dose: 500 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
IMATINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
38.8 ng × h/mL
400 mg 1 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
IMATINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
89.9 ng × h/mL
600 mg 1 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
IMATINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
38.8 μg × h/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IMATINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
63.7 μg × h/mL
600 mg 2 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IMATINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
97.3 μg × h/mL
500 mg 2 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IMATINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
10.1 μg × h/mL
600 mg 2 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CGP-74588 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
19.7 μg × h/mL
500 mg 2 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CGP-74588 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
15.8 h
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IMATINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
17 h
500 mg 2 times / day steady-state, oral
dose: 500 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
IMATINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
14.8 h
400 mg 1 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
IMATINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
15.6 h
600 mg 1 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
IMATINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
83.3 h
600 mg 2 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IMATINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
23.6 h
500 mg 2 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IMATINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
50.8 h
600 mg 2 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CGP-74588 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
10.2 h
500 mg 2 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CGP-74588 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
4%
500 mg 2 times / day steady-state, oral
dose: 500 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
IMATINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
4%
400 mg 1 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
IMATINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
4%
600 mg 1 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
IMATINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
5%
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IMATINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
500 mg 2 times / day steady, oral
MTD
Dose: 500 mg, 2 times / day
Route: oral
Route: steady
Dose: 500 mg, 2 times / day
Sources:
unhealthy, 53.3 years (range: 29.8–69.9 years)
n = 35
Health Status: unhealthy
Condition: malignant glioma
Age Group: 53.3 years (range: 29.8–69.9 years)
Sex: M+F
Population Size: 35
Sources:
400 mg 2 times / day steady, oral
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy, 53.3 years (range: 29.8–69.9 years)
n = 35
Health Status: unhealthy
Condition: malignant glioma
Age Group: 53.3 years (range: 29.8–69.9 years)
Sex: M+F
Population Size: 35
Sources:
DLT: Transaminases increased...
Dose limiting toxicities:
Transaminases increased (grade 3, 1 patient)
Sources:
600 mg 2 times / day steady, oral
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
unhealthy, 53.3 years (range: 29.8–69.9 years)
n = 35
Health Status: unhealthy
Condition: malignant glioma
Age Group: 53.3 years (range: 29.8–69.9 years)
Sex: M+F
Population Size: 35
Sources:
DLT: Neutropenia, Hypocalcemia...
Dose limiting toxicities:
Neutropenia (grade 3, 2 patients)
Hypocalcemia (grade 4, 2 patients)
Hypophosphatemia (grade 4, 2 patients)
Hypokalemia (grade 3, 2 patients)
Nausea (grade 3, 2 patients)
Emesis (grade 3, 2 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Transaminases increased grade 3, 1 patient
DLT
400 mg 2 times / day steady, oral
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy, 53.3 years (range: 29.8–69.9 years)
n = 35
Health Status: unhealthy
Condition: malignant glioma
Age Group: 53.3 years (range: 29.8–69.9 years)
Sex: M+F
Population Size: 35
Sources:
Emesis grade 3, 2 patients
DLT
600 mg 2 times / day steady, oral
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
unhealthy, 53.3 years (range: 29.8–69.9 years)
n = 35
Health Status: unhealthy
Condition: malignant glioma
Age Group: 53.3 years (range: 29.8–69.9 years)
Sex: M+F
Population Size: 35
Sources:
Hypokalemia grade 3, 2 patients
DLT
600 mg 2 times / day steady, oral
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
unhealthy, 53.3 years (range: 29.8–69.9 years)
n = 35
Health Status: unhealthy
Condition: malignant glioma
Age Group: 53.3 years (range: 29.8–69.9 years)
Sex: M+F
Population Size: 35
Sources:
Nausea grade 3, 2 patients
DLT
600 mg 2 times / day steady, oral
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
unhealthy, 53.3 years (range: 29.8–69.9 years)
n = 35
Health Status: unhealthy
Condition: malignant glioma
Age Group: 53.3 years (range: 29.8–69.9 years)
Sex: M+F
Population Size: 35
Sources:
Neutropenia grade 3, 2 patients
DLT
600 mg 2 times / day steady, oral
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
unhealthy, 53.3 years (range: 29.8–69.9 years)
n = 35
Health Status: unhealthy
Condition: malignant glioma
Age Group: 53.3 years (range: 29.8–69.9 years)
Sex: M+F
Population Size: 35
Sources:
Hypocalcemia grade 4, 2 patients
DLT
600 mg 2 times / day steady, oral
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
unhealthy, 53.3 years (range: 29.8–69.9 years)
n = 35
Health Status: unhealthy
Condition: malignant glioma
Age Group: 53.3 years (range: 29.8–69.9 years)
Sex: M+F
Population Size: 35
Sources:
Hypophosphatemia grade 4, 2 patients
DLT
600 mg 2 times / day steady, oral
Dose: 600 mg, 2 times / day
Route: oral
Route: steady
Dose: 600 mg, 2 times / day
Sources:
unhealthy, 53.3 years (range: 29.8–69.9 years)
n = 35
Health Status: unhealthy
Condition: malignant glioma
Age Group: 53.3 years (range: 29.8–69.9 years)
Sex: M+F
Population Size: 35
Sources:
OverviewDrug as perpetrator​Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia.
2001
Sarcoma.
2001
STI571: targeting BCR-ABL as therapy for CML.
2001
Mechanisms of transformation by the BCR/ABL oncogene.
2001 Apr
ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy.
2001 Aug
Targeting protein kinases for tumor therapy.
2001 Aug
PDGF-beta receptor expression in the dorsocaudal brainstem parallels hypoxic ventilatory depression in the developing rat.
2001 Aug
Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis.
2001 Aug 1
Cutaneous reactions to STI571.
2001 Aug 23
[New target-aimed molecular cancer treatment of chronic myeloid leukemia and gastrointestinal stromal tumor].
2001 Aug 27
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.
2001 Aug 3
Bcr-Abl inhibition as a modality of CML therapeutics.
2001 Aug 31
Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients.
2001 Feb
Mechanisms of resistance to imatinib (STI571) and prospects for combination with conventional chemotherapeutic agents.
2001 Feb
Perspectives on the future of chronic myeloid leukemia treatment.
2001 Jul
Implications of imatinib mesylate for hematopoietic stem cell transplantation.
2001 Jul
Interferon-alfa-based treatment of chronic myeloid leukemia and implications of signal transduction inhibition.
2001 Jul
Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
2001 Jul
Signal transduction inhibition: results from phase I clinical trials in chronic myeloid leukemia.
2001 Jul
Clinical trials referral resource. ST1571.
2001 Jul
[STI571 and gastro intestinal stromal tumors].
2001 Jul
[Leukemogenesis and new therapy development: the example of chronic myelogenous leukemia].
2001 Jul
Chronic myelogenous leukaemia--new therapeutic principles.
2001 Jul
Approval heralds new generation of kinase inhibitors?
2001 Jul
Anti-cancer drug success emerges from molecular biology origins.
2001 Jul
New drug targets genetic malfunction in chronic myeloid leukemia.
2001 Jul 15
New-age drug meets resistance.
2001 Jul 19
After 30 years of laboratory work, a quick approval for STI571.
2001 Jul 4
STI571 revolution: can the newer targeted drugs measure up?
2001 Jul 4
Current treatment approaches for chronic myelogenous leukemia.
2001 Jul-Aug
Quick success for cancer kinase treatment.
2001 Jun
Recent success with the tyrosine kinase inhibitor STI-571--lessons for targeted therapy of cancer.
2001 Mar
Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells.
2001 May
STI571: a gene product-targeted therapy for leukemia.
2001 May
Progenitor cells from patients with advanced phase chronic myeloid leukaemia respond to STI571 in vitro and in vivo.
2001 Nov
STI571: a magic bullet?
2001 Oct
Chronic myeloid leukemia: current treatment options.
2001 Oct 1
Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells.
2001 Oct 12
Improving the management of chronic myeloid leukaemia.
2001 Sep
[Chronic myelogenous leukemia].
2001 Sep
Pharmacologic inhibition of the Bcr-Abl kinase with STI571: a novel, safe, and effective therapy for chronic myeloid leukemia.
2001 Sep
A possible role for STI571 in the treatment of idiopathic myelofibrosis.
2001 Sep
Treatment of leukemia relapse after allogeneic hematopoietic stem cell transplantation by donor lymphocyte infusion and STI-571.
2001 Sep
Inhibition of tyrosine kinase activity induces caspase-dependent apoptosis in anaplastic large cell lymphoma with NPM-ALK (p80) fusion protein.
2001 Sep
Cancer in the crosshairs.
2001 Sep
Cancer treatment in the STI571 era: what will change?
2001 Sep 15
Roots of clinical resistance to STI-571 cancer therapy.
2001 Sep 21
Roots of clinical resistance to STI-571 cancer therapy.
2001 Sep 21
Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.
2001 Sep 27
Small molecule: large hopes.
2001 Sep-Oct
Patents

Sample Use Guides

The prescribed dose should be administered orally, with a meal and a large glass of water. Doses of 400 mg or 600 mg should be administered once daily, whereas a dose of 800 mg should be administered as 400 mg twice a day. Treatment may be continued as long as there is no evidence of progressive disease or unacceptable toxicity.
Route of Administration: Oral
In Vitro Use Guide
Imatinib (CGP 57148) was tested for growth inhibition of EGF-dependent BALB/MK cells, the H-ras-transformed T24 bladder carcinoma line, and IL-3-dependent growth of FDC-Pl cells. The compound showed only weak antiproliferative activity against these cell lines, with IC50 values of 12.7 uM, 9.4 uM, and 29.2 uM, respectively. However, when tested on v-abl-transformed PB-3c cells, incubation with CGP 57148 resulted in potent growth inhibition even in the presence of exogenous IL-3 (IC50 values, 0.11 uM without IL-3 and 0.9 uM with IL-3). Similar results were obtained using v-sis-transformed BALB/c 3T3 cells, which grow in response to autocrine PDGF production (IC50, 0.33 uM).
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:07:30 UTC 2021
Edited
by admin
on Fri Jun 25 21:07:30 UTC 2021
Record UNII
8A1O1M485B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
IMATINIB MESYLATE
HSDB   ORANGE BOOK   USAN   VANDF  
USAN  
Official Name English
IMATINIB MESYLATE [USAN]
Common Name English
IMATINIB METHANE SULFONATE
Common Name English
IMATINIB METHANESULFONATE
MI  
Common Name English
IMATINIB ACCORD
Brand Name English
IMATINIB MESILATE [MART.]
Common Name English
IMATINIB MESILATE [EP MONOGRAPH]
Common Name English
QTI571
Code English
IMATINIB MESILATE
JAN   MART.   WHO-DD  
Common Name English
IMATINIB MESYLATE [ORANGE BOOK]
Common Name English
NSC-716051
Code English
IMATINIB MESYLATE [HSDB]
Common Name English
GLIVEC
Common Name English
BENZAMIDE, 4-((4-METHYL-1-PIPERAZINYL)METHYL)-N-(4-METHYL-3-((4-(3-PYRIDINYL)-2-PYRIMIDINYL)AMINOPHENYL)-, METHANESULFONATE SALT
Common Name English
BENZAMIDE, 4-((4-METHYL-1-PIPERAZINYL)METHYL)-N-(4-METHYL-3-((4-(3-PYRIDINYL)-2-PYRIMIDINYL)AMINOPHENYL)-, METHANESULPHONATE SALT
Common Name English
IMATINIB MESYLATE [VANDF]
Common Name English
IMATINIB MESILATE [JAN]
Common Name English
IMATINIB MEDAC
Brand Name English
GLEEVEC
Brand Name English
STI571
Code English
IMATINIB METHANESULFONATE [MI]
Common Name English
IMATINIB MESILATE [WHO-DD]
Common Name English
STI-571
Code English
STI 571
Code English
QTI-571
Code English
IMATINIB (AS MESILATE)
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 209005
Created by admin on Fri Jun 25 21:07:30 UTC 2021 , Edited by admin on Fri Jun 25 21:07:30 UTC 2021
EMA ASSESSMENT REPORTS IMATINIB ACCORD (AUTHORIZED: PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA
Created by admin on Fri Jun 25 21:07:30 UTC 2021 , Edited by admin on Fri Jun 25 21:07:30 UTC 2021
EMA ASSESSMENT REPORTS IMATINIB MEDAC (AUTHORIZED: HYPEREOSINOPHILIC SYNDROME)
Created by admin on Fri Jun 25 21:07:30 UTC 2021 , Edited by admin on Fri Jun 25 21:07:30 UTC 2021
EMA ASSESSMENT REPORTS IMATINIB ACTAVIS (AUTHORIZED: LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE)
Created by admin on Fri Jun 25 21:07:30 UTC 2021 , Edited by admin on Fri Jun 25 21:07:30 UTC 2021
EMA ASSESSMENT REPORTS GLIVEC (AUTHORIZED: LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE)
Created by admin on Fri Jun 25 21:07:30 UTC 2021 , Edited by admin on Fri Jun 25 21:07:30 UTC 2021
EMA ASSESSMENT REPORTS GLIVEC (AUTHORIZED: PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA)
Created by admin on Fri Jun 25 21:07:30 UTC 2021 , Edited by admin on Fri Jun 25 21:07:30 UTC 2021
FDA ORPHAN DRUG 209205
Created by admin on Fri Jun 25 21:07:30 UTC 2021 , Edited by admin on Fri Jun 25 21:07:30 UTC 2021
FDA ORPHAN DRUG 149201
Created by admin on Fri Jun 25 21:07:30 UTC 2021 , Edited by admin on Fri Jun 25 21:07:30 UTC 2021
NCI_THESAURUS C155700
Created by admin on Fri Jun 25 21:07:30 UTC 2021 , Edited by admin on Fri Jun 25 21:07:30 UTC 2021
EMA ASSESSMENT REPORTS IMATINIB MEDAC (AUTHORIZED: MYELODYPLASTIC-MYELOPROLIFERATIVE DISEASES)
Created by admin on Fri Jun 25 21:07:30 UTC 2021 , Edited by admin on Fri Jun 25 21:07:30 UTC 2021
EMA ASSESSMENT REPORTS GLIVEC (AUTHORIZED: HYPEREOSINOPHILIC SYNDROME)
Created by admin on Fri Jun 25 21:07:30 UTC 2021 , Edited by admin on Fri Jun 25 21:07:30 UTC 2021
EMA ASSESSMENT REPORTS GLIVEC (AUTHORIZED: MYELODYPLASTIC-MYELOPROLIFERATIVE DISEASES)
Created by admin on Fri Jun 25 21:07:30 UTC 2021 , Edited by admin on Fri Jun 25 21:07:30 UTC 2021
EMA ASSESSMENT REPORTS IMATINIB ACCORD (AUTHORIZED: MYELODYPLASTIC-MYELOPROLIFERATIVE DISEASES)
Created by admin on Fri Jun 25 21:07:30 UTC 2021 , Edited by admin on Fri Jun 25 21:07:30 UTC 2021
EMA ASSESSMENT REPORTS IMATINIB MEDAC (AUTHORIZED: PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA)
Created by admin on Fri Jun 25 21:07:30 UTC 2021 , Edited by admin on Fri Jun 25 21:07:30 UTC 2021
FDA ORPHAN DRUG 428914
Created by admin on Fri Jun 25 21:07:30 UTC 2021 , Edited by admin on Fri Jun 25 21:07:30 UTC 2021
EMA ASSESSMENT REPORTS IMATINIB ACCORD (AUTHORIZED: LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE)
Created by admin on Fri Jun 25 21:07:30 UTC 2021 , Edited by admin on Fri Jun 25 21:07:30 UTC 2021
FDA ORPHAN DRUG 209105
Created by admin on Fri Jun 25 21:07:30 UTC 2021 , Edited by admin on Fri Jun 25 21:07:30 UTC 2021
EMA ASSESSMENT REPORTS IMATINIB ACCORD (AUTHORIZED:HYPEREOSINOPHILIC SYNDROME)
Created by admin on Fri Jun 25 21:07:30 UTC 2021 , Edited by admin on Fri Jun 25 21:07:30 UTC 2021
EU-Orphan Drug EU/3/01/021
Created by admin on Fri Jun 25 21:07:30 UTC 2021 , Edited by admin on Fri Jun 25 21:07:30 UTC 2021
EMA ASSESSMENT REPORTS IMATINIB TEVA (AUTHORIZED:
Created by admin on Fri Jun 25 21:07:30 UTC 2021 , Edited by admin on Fri Jun 25 21:07:30 UTC 2021
FDA ORPHAN DRUG 208805
Created by admin on Fri Jun 25 21:07:30 UTC 2021 , Edited by admin on Fri Jun 25 21:07:30 UTC 2021
FDA ORPHAN DRUG 741420
Created by admin on Fri Jun 25 21:07:30 UTC 2021 , Edited by admin on Fri Jun 25 21:07:30 UTC 2021
EMA ASSESSMENT REPORTS IMATINIB MEDAC (AUTHORIZED: LEUKEMIA, MYELOMONOCYTIC, CHRONIC)
Created by admin on Fri Jun 25 21:07:30 UTC 2021 , Edited by admin on Fri Jun 25 21:07:30 UTC 2021
Code System Code Type Description
HSDB
7142
Created by admin on Fri Jun 25 21:07:30 UTC 2021 , Edited by admin on Fri Jun 25 21:07:30 UTC 2021
PRIMARY
RXCUI
284924
Created by admin on Fri Jun 25 21:07:30 UTC 2021 , Edited by admin on Fri Jun 25 21:07:30 UTC 2021
PRIMARY RxNorm
EPA CompTox
220127-57-1
Created by admin on Fri Jun 25 21:07:30 UTC 2021 , Edited by admin on Fri Jun 25 21:07:30 UTC 2021
PRIMARY
MERCK INDEX
M6213
Created by admin on Fri Jun 25 21:07:30 UTC 2021 , Edited by admin on Fri Jun 25 21:07:30 UTC 2021
PRIMARY Merck Index
EVMPD
SUB12517MIG
Created by admin on Fri Jun 25 21:07:30 UTC 2021 , Edited by admin on Fri Jun 25 21:07:30 UTC 2021
PRIMARY
DRUG BANK
DBSALT000098
Created by admin on Fri Jun 25 21:07:30 UTC 2021 , Edited by admin on Fri Jun 25 21:07:30 UTC 2021
PRIMARY
PUBCHEM
123596
Created by admin on Fri Jun 25 21:07:30 UTC 2021 , Edited by admin on Fri Jun 25 21:07:30 UTC 2021
PRIMARY
ChEMBL
CHEMBL941
Created by admin on Fri Jun 25 21:07:30 UTC 2021 , Edited by admin on Fri Jun 25 21:07:30 UTC 2021
PRIMARY
NCI_THESAURUS
C1687
Created by admin on Fri Jun 25 21:07:30 UTC 2021 , Edited by admin on Fri Jun 25 21:07:30 UTC 2021
PRIMARY
FDA UNII
8A1O1M485B
Created by admin on Fri Jun 25 21:07:30 UTC 2021 , Edited by admin on Fri Jun 25 21:07:30 UTC 2021
PRIMARY
CAS
220127-57-1
Created by admin on Fri Jun 25 21:07:30 UTC 2021 , Edited by admin on Fri Jun 25 21:07:30 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY